SEC Comment Letter for CTI BIOPHARMA CORP (CIK 0000891293) — Aug 19, 2022
CTI BIOPHARMA CORP (CIK 0000891293)
Date: Aug. 19, 2022 · CIK: 0000891293 · Accession: 0000000000-22-008965
AI Filing Summary & Sentiment
File numbers found in text: 333-266926
Letter
United States securities and exchange commission logo August 19, 2022 Adam Craig, M.D., Ph.D. Chief Executive Officer CTI BioPharma Corp. 3101 Western Avenue, Suite 800 Seattle, WA 98121 Re:CTI BioPharma Corp. Registration Statement on Form S-3 Filed August 17, 2022 File No. 333-266926 Dear Dr. Craig: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Branden C. Berns
Show Raw Text
United States securities and exchange commission logo
August 19, 2022
Adam Craig, M.D., Ph.D.
Chief Executive Officer
CTI BioPharma Corp.
3101 Western Avenue, Suite 800
Seattle, WA 98121
Re:CTI BioPharma Corp.
Registration Statement on Form S-3
Filed August 17, 2022
File No. 333-266926
Dear Dr. Craig:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Branden C. Berns